PPCB
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Propanc Biopharma reports that its lead asset PRP reprograms chemotherapy-resistant pancreatic cancer cellsOct 16, 2026
- Propanc Biopharma announces publication of a pilot study showing potent anti-tumor activity of its PRP pancreatic proenzyme formulation in pancreatic and ovarian cancersOct 14, 2026
- Propanc Biopharma reports 90% tumor growth inhibition with PRP in pancreatic cancer models, highlighting a differentiated profile versus Revolution Medicines' daraxonrasibOct 7, 2026